开盘$531.53
昨收$542.50
当日区间$531.53 – $548.76
成交量1.27M
市值$138.71B
市盈率（TTM）35.2
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例96.9%+0.00 个百分点，较上季度
持仓机构数2,129+32 ，较上季度
内部人近期交易28次买入 / 22次卖出净买入
空头持仓比例1.68% 占流通股回补天数 3.4 · 截至 15 Oct 2026
卖空成交量占比17.9%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：−$45.25M（8个净流入日，12个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有44.3%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从1.55%升至1.68%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +459,747 | 0.5% |
| Montrusco Bolton Investments Inc. | Mutual Fund | 2026/Q3 | +149,888 | 0.1% |
| Putnam LLC | Mutual Fund | 2026/Q3 | +2,737,137 | 1.1% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +466,738 | 0.2% |
| AQR Capital Management | Hedge Fund | 2026/Q3 | +437,893 | 0.2% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +437,587 | 0.2% |
| Hudson Bay Capital Management LP | Hedge Fund | 2026/Q3 | +345,440 | 0.2% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +323,793 | 2.9% |
| Victory Capital Management Inc. | Mutual Fund | 2026/Q3 | +284,631 | 0.9% |
| Jennison Associates LLC | Mutual Fund | 2026/Q3 | +258,471 | 1.2% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +226,839 | 0.2% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +222,316 | 0.3% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +201,686 | 0.2% |
| Sparinvest SA (Luxembourg) | Mutual Fund | 2026/Q3 | +196,334 | 0.1% |
| Susquehanna International Group, LLP | Private Company | 2026/Q3 | +185,692 | 0.1% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | Daniel Brennan | Independent Director | Other Acquisition | +795 | $503.47 | 795 |
| 14 Oct 2026 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +92 | – | 15,865 |
| 14 Oct 2026 | Alan Garber | Independent Director | Other Derivative Acquisition | +29 | – | 95 |
| 7 Sep 2026 | Jasper van Grunsven | Executive VP & Chief Pain & New Product Planning Officer | Other Acquisition | +8,682 | – | 8,682 |
| 27 Aug 2026 | Kristen Ambrose | Chief Accounting Officer | Other Acquisition | +5,000 | – | 11,624 |
| 26 Aug 2026 | Bruce Sachs | Lead Independent Director | Other Disposition | -6,000 | – | 39,000 |
| 20 Jul 2026 | Amit Sachdev | Executive VP & Chief Patient and External Affairs Officer | Other Acquisition | +8,251 | – | 74,031 |
| 20 Jul 2026 | Ourania Tatsis | Executive VP & Chief Product Affairs Officer | Other Acquisition | +8,251 | – | 53,572 |
| 14 Jul 2026 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +99 | – | 15,772 |
| 14 Jul 2026 | Alan Garber | Independent Director | Other Derivative Acquisition | +31 | – | 65 |
| 1 Jul 2026 | Ourania Tatsis | Executive VP & Chief Product Affairs Officer | Automatic Disposition | -1,500 | $524.99 | 45,321 |
| 1 Jul 2026 | Duncan McKechnie | Executive Vice President | Automatic Disposition | -1,541 | $519.00 | 11,001 |
| 30 Jun 2026 | Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | Automatic Disposition | -828 | $502.71 | 19,131 |
| 25 Jun 2026 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -596 | $482.50 | 15,337 |
| 17 Jun 2026 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,020 | $462.17 | 15,933 |
| 14 Jun 2026 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -4,062 | $450.00 | 16,953 |
| 4 Jun 2026 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,745 | $450.00 | 21,015 |
| 31 May 2026 | Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | Automatic Disposition | -828 | $439.91 | 19,959 |
| 28 May 2026 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,974 | $450.00 | 22,760 |
| 14 May 2026 | Mark Bunnage | Chief Scientific Officer | Automatic Disposition | -33 | $453.45 | 7,284 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 4,263,331 | 1.7% | 3.4 |
| 30 Sep 2026 | 4,503,200 | 1.8% | 4.2 |
| 15 Sep 2026 | 4,716,867 | 1.9% | 5.0 |
| 31 Aug 2026 | 4,659,749 | 1.8% | 4.5 |
| 14 Aug 2026 | 4,146,973 | 1.6% | 3.1 |
| 31 Jul 2026 | 3,942,936 | 1.6% | 3.0 |
暂无评论——快来第一个聊聊 VRTX。
登录后参与讨论。